How good are publicly available web services that predict bioactivity profiles for drug repurposing?Footnote^$

$ Presented at the 9th International Symposium on Computational Methods in Toxicology and Pharmacology Integrating Internet Resources, CMTPI-2017, 27–30 October 2017, Goa, India.

References

• T.T. Ashburn and K.B. Thor, Drug repositioning: Identifying and developing new uses for existing drugs, Nat. Rev. Drug Discov. 3 (2004), pp. 673–683.
   PubMed Web of Science ®Google Scholar
• C. Chong and D. Sullivan, New uses for old drugs, Nature 448 (2007), p. 645.
   PubMed Web of Science ®Google Scholar
• A.M. Thayer, Drug repurposing, Chem. Eng. News 90 (2012), pp. 15–25.
   Web of Science ®Google Scholar
• T.I. Oprea and J.P. Overington, Computational and practical aspects of drug repositioning, Assay Drug. Dev. Technol. 13 (2015), pp. 1–8.
   PubMed Web of Science ®Google Scholar
• D. Cavalla, APT drug R&D: The right active ingredient in the right presentation for the right therapeutic use, Nat. Rev. Drug Discov. 8 (2009), pp. 849–853.
   PubMed Web of Science ®Google Scholar
• S. Naylor and J.M. Schonfeld, Therapeutic drug repurposing, repositioning and rescue - Part I: Overview, Drug Discov. World 16 (2014), pp. 49–62.
   Google Scholar
• S. Ekins, A.J. Williams, M.D. Krasowski, and J.S. Freundlich, In silico repositioning of approved drugs for rare and neglected diseases, Drug Discov. Today 16 (2011), pp. 298–310.
   PubMed Web of Science ®Google Scholar
• J. Strovel, S.G. Sittampalam, N.P. Coussens, M. Hughes, J. Inglese, A. Kurtz, A. Andalibi, L. Patton, C. Austin, M. Baltezor, M. Beckloff, M. Weingarten, and S. Weir, Early drug discovery and development guidelines: For academic researchers, collaborators, and start-up companies, in assay guidance manual, S.G. Sittampalam, N.P. Coussens, K. Brimacombe, A. Grossman, M. Arkin, D. Auld, C. Austin, J. Baell, B. Bejcek, T.D.Y. Chung, J.L. Dahlin, V. Devanaryan, T. L. Foley, M. Glicksman, M.D. Hall, J.V. Hass, J. Inglese, P.W. Iversen, S.D. Kahl, S.C. Kales, M. Lal-Nag, Z. Li, J. McGee, O. McManus, T. Riss, O.J. Trask, J. R. Weidner, M. Xia, and X. Xu, eds., Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD), 2004, pp. 261–263.
   Google Scholar
• N.K. Litterman, M. Rhee, D.C. Swinney, and S. Ekins, Collaboration for rare disease drug discovery research, F1000Research, 3 (2014), pp. 4–7.
   PubMedGoogle Scholar
• J.R. Everett, Academic drug discovery: Current status and prospects, Expert Opin. Drug Discov. 10 (2015), pp. 937–944.
   PubMed Web of Science ®Google Scholar
• T. Hammonds, Academic-Pharma drug discovery alliances: Seeking ways to eliminate the valley of death, Future Med. Chem. 7 (2015), pp. 1891–1899.
   PubMed Web of Science ®Google Scholar
• N. Novac, Challenges and opportunities of drug repositioning, Trends Pharmacol. Sci. 34 (2013), pp. 267–272.
   PubMed Web of Science ®Google Scholar
• R. Huang, N. Southall, Y. Wang, A. Yasgar, P. Shinn, A. Jadhav, D.T. Nguyen, and C.P. Austin, The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics, Sci. Transl. Med. 3 (2011), pp. 1–12.
   Web of Science ®Google Scholar
• Y. Pan, T. Cheng, Y. Wang, and S.H. Bryant, Pathway analysis for drug repositioning based on public database mining, J. Chem. Inf. Model. 54 (2014), pp. 407–418.
   PubMed Web of Science ®Google Scholar
• J. Yang, Z. Li, X. Fan, and Y. Cheng, Drug-disease association and drug-repositioning predictions in complex diseases using causal inference-probabilistic matrix factorization, J. Chem. Inf. Model. 54 (2014), pp. 2562–2569.
   PubMed Web of Science ®Google Scholar
• H. Iwata, R. Sawada, S. Mizutani, and Y. Yamanishi, Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data, J. Chem. Inf. Model. 55 (2015), pp. 446–459.
   PubMed Web of Science ®Google Scholar
• D. Jang, S. Lee, J. Lee, K. Kim, and D. Lee, Inferring new drug indications using the complementarity between clinical disease signatures and drug effects, J. Biomed. Inform. 59 (2016), pp. 248–257.
   PubMed Web of Science ®Google Scholar
• D. Cavalla, Predictive methods in drug repurposing: Gold mine or just a bigger haystack?, Drug Discov. Today 18 (2013), pp. 523–532.
   PubMed Web of Science ®Google Scholar
• G. Jin and S.T.C. Wong, Toward better drug repositioning: Prioritizing and integrating existing methods into efficient pipelines, Drug Discov. Today 19 (2014), pp. 637–644.
   PubMed Web of Science ®Google Scholar
• P.V. Pogodin, A.A. Lagunin, D.A. Filimonov, and V.V. Poroikov, PASS targets: Ligand-based multi-target computational system based on a public data and naïve Bayes approach, SAR QSAR Environ. Res. 26 (2015), pp. 783–793.
   PubMed Web of Science ®Google Scholar
• A. Lavecchia and C. Cerchia, In silico methods to address polypharmacology: Current status, applications and future perspectives, Drug Discov. Today 21 (2016), pp. 288–298.
   PubMed Web of Science ®Google Scholar
• Institute of Biomedical Chemistry. Way2Drug, Institute of Biomedical Chemistry, Moscow, Russia, 2017. Software available at http://www.way2drug.com/.
   Google Scholar
• University of California in San Francisco. Similarity ensemble approach, University of California in San Francisco, San Francisco, CA, USA, 2017. Software available at http://sea.bkslab.org/.
   Google Scholar
• Charité-University Medicine Berlin, SuperPred webserver, Charité-University Medicine Berlin, Berlin, Germany, 2017. Software available at http://prediction.charite.de/.
   Google Scholar
• Swiss Institute of Bioinformatics, SwissTargetPrediction, Swiss Institute of Bioinformatics, Lausanne, Switzerland, 2017. Software available at http://www.swisstargetprediction.ch/.
   Google Scholar
• Technical University of Denmark, ChemProt version 3.0, Technical University of Denmark, Lyngby, Denmark, 2017. Software available at http://potentia.cbs.dtu.dk/ChemProt/.
   Google Scholar
• Shanghai Institute of Materia Medica, Chinese Academy of Sciences, TarPred, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China, 2016. Software available at http://202.127.19.75:5555/.
   Google Scholar
• University of Pittsburgh School of Pharmacy, TargetHunter, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA, 2017. Software available at www.cbligand.org/TargetHunter.
   Google Scholar
• A. Lagunin, A. Stepanchikova, D. Filimonov, and V. Poroikov, PASS: Prediction of activity spectra for biologically active substances, Bioinformatics 16 (2000), pp. 747–748.
   PubMed Web of Science ®Google Scholar
• M.J. Keiser, B.L. Roth, B.N. Armbruster, P. Ernsberger, J.J. Irwin, and B.K. Shoichet, Relating protein pharmacology by ligand chemistry, Nat. Biotechnol. 25 (2007), pp. 197–206.
   PubMed Web of Science ®Google Scholar
• M. Dunkel, S. Gunther, J. Ahmed, B. Wittig, and R. Preissner, SuperPred: Drug classification and target prediction, Nucleic Acids Res. 36 (2008), pp. W55–W59.
   PubMed Web of Science ®Google Scholar
• X. Liu, Y. Gao, J. Peng, Y. Xu, Y. Wang, N. Zhou, J. Xing, X. Luo, H. Jiang, and M. Zheng, TarPred: A web application for predicting therapeutic and side effect targets of chemical compounds, Bioinformatics 31 (2015), pp. 1–2.
   PubMed Web of Science ®Google Scholar
• X. Liu, Y. Xu, S. Li, Y. Wang, J. Peng, C. Luo, M. Zheng, K. Chen, and H. Jiang, In silico target fishing: Addressing a “Big Data” problem by ligand-based similarity rankings with data fusion, J. Cheminform. 6 (2014), p. 33.
   PubMed Web of Science ®Google Scholar
• D. Gfeller, O. Michielin, and V. Zoete, Shaping the interaction landscape of bioactive molecules, Bioinformatics 29 (2013), pp. 3073–3079.
   PubMed Web of Science ®Google Scholar
• D. Gfeller, A. Grosdidier, M. Wirth, A. Daina, O. Michielin, and V. Zoete, SwissTargetPrediction: A web server for target prediction of bioactive small molecules, Nucleic Acids Res. 42 (2014), pp. W32–W38.
   PubMed Web of Science ®Google Scholar
• S.K. Kjærulff, L. Wich, J. Kringelum, U.P. Jacobsen, I. Kouskoumvekaki, K. Audouze, O. Lund, S. Brunak, T.I. Oprea, and O. Taboureau, ChemProt-2.0: Visual navigation in a disease chemical biology database, Nucleic Acids Res. 41 (2013), pp. D464–D469.
   PubMed Web of Science ®Google Scholar
• D.A. Filimonov, A.A. Lagunin, T.A. Gloriozova, A.V. Rudik, D.S. Druzhilovskii, P.V. Pogodin, and V.V. Poroikov, Prediction of the biological activity spectra of organic compounds using the pass online web resource, Chem. Heterocycl. Compd. 50 (2014), pp. 444–457.
   Web of Science ®Google Scholar
• J. Nickel, B.-O. Gohlke, J. Erehman, P. Banerjee, W.W. Rong, A. Goede, M. Dunkel, and R. Preissner, SuperPred: Update on drug classification and target prediction, Nucleic Acids Res. 42 (2014), pp. 26–31.
   PubMed Web of Science ®Google Scholar
• J. Kringelum, S.K. Kjaerulff, S. Brunak, O. Lund, T.I. Oprea, and O. Taboureau, ChemProt-3.0: A global chemical biology diseases mapping, Database 2016 (2016), pp. 1–7.
   Google Scholar
• L. Wang, C. Ma, P. Wipf, H. Liu, W. Su, and X.-Q. Xie, TargetHunter: An in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database, AAPS J. 15 (2013), pp. 395–406.
   PubMed Web of Science ®Google Scholar
• T.I. Oprea, J.E. Bauman, C.G. Bologa, T. Buranda, A. Chigaev, B.S. Edwards, J.W. Jarvik, H.D. Gresham, M.K. Haynes, B. Hjelle, R. Hromas, L. Hudson, D.A. Mackenzie, C.Y. Muller, J.C. Reed, P.C. Simons, Y. Smagley, J. Strouse, Z. Surviladze, T. Thompson, O. Ursu, A. Waller, A Wandinger-Ness, S.S. Winter, Y. Wu, S.M. Young, R.S. Larson, C. Willman, and L.A. Sklar, Drug repurposing from an academic perspective, Drug Discov. Today Ther. Strateg. 8 (2012), pp. 61–69.
   Google Scholar
• J. Frearson and P. Wyatt, Drug discovery in academia: The third way?, Expert Opin. Drug Discov. 5 (2010), pp. 909–919.
   PubMed Web of Science ®Google Scholar
• H. Schultz Kirkegaard and F. Valentin, Academic drug discovery centres: The economic and organisational sustainability of an emerging model, Drug Discov. Today 19 (2014), pp. 1699–1710.
   PubMed Web of Science ®Google Scholar
• A.S. Kesselheim, Y.T. Tan, and J. Avorn, The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs, Health Aff. 34 (2015), pp. 286–293.
   PubMed Web of Science ®Google Scholar
• P.I. Arvidsson, K. Sandberg, and K. Forsberg-Nilsson, Open for collaboration: An academic platform for drug discovery and development at SciLifeLab, Drug Discov. Today 21 (2016), pp. 1690–1698.
   PubMed Web of Science ®Google Scholar
• K. Anusevicius, V. Mickevicius, M. Stasevych, V. Zvarych, O. Komarovska-Porokhnyavets, V. Novikov, O. Tarasova, T. Gloriozova, and V. Poroikov, Synthesis and chemoinformatics analysis of N-aryl-β-alanine derivatives, Res. Chem. Intermed. 41 (2015), pp. 7517–7540.
   Web of Science ®Google Scholar
• M. Luo, X.S. Wang, and A. Tropsha, Comparative analysis of QSAR-based vs. chemical similarity based predictors of GPCRs binding affinity, Mol. Inform. 35 (2016), pp. 36–41.
   PubMed Web of Science ®Google Scholar
• D.S. Druzhilovskiy, A.V. Rudik, D.A. Filimonov, A.A. Lagunin, T.A. Gloriozova, and V.V. Poroikov, Online resources for the prediction of biological activity of organic compounds, Russ. Chem. Bull. 65 (2016), pp. 384–393.
   Web of Science ®Google Scholar
• Weizmann Institute of Science, GeneCards, Weizmann Institute of Science, Rehovot, Israel, 2017; Software available at http://www.genecards.org/.
   Google Scholar
• EMBL-EBI, UniProt, EMBL-EBI, Hinxton, UK, 2017. Software available at http://www.uniprot.org/.
   Google Scholar
• EMBL-EBI, ChEMBL, EMBL-EBI, Hinxton, UK, 2017. Software available at https://www.ebi.ac.uk/chembl/.
   Google Scholar
• Peter Ertl and Bruno Bienfait, 2017, JSME Homepage; software available at http://peter-ertl.com/jsme/.
   Google Scholar
• ChemAxon, ChemAxon, Budapest, Hungary, 2017. Software available at https://www.chemaxon.com/.
   Google Scholar
• GVK Biosciences, Drug repurposing portal, GVK Biosciences, Hyderabad, India, 2017. Software available at http://www.drugrepurposingportal.com/index.html.
   Google Scholar
• Numedicus, Drug repurposing info, Numedicus, Cambridge, UK, 2017. Software available at http://www.drugrepurposing.info/.
   Google Scholar
• International Rare Diseases Research Consortium, Drugnet: A novel drug repurposing webtool – IRDiRC, International Rare Diseases Research Consortium, Paris, France, 2017; software available at http://www.irdirc.org/drugnet-a-novel-drug-repurposing-webtool/.
   Google Scholar
• J. Langedijk, A.K. Mantel-Teeuwisse, D.S. Slijkerman, and M.H.D.B. Schutjens, Drug repositioning and repurposing: Terminology and definitions in literature, Drug Discov. Today 20 (2015), pp. 1027–1034.
   PubMed Web of Science ®Google Scholar
• G. Yacila and Y. Sari, Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis, Curr. Med. Chem. 21 (2014), pp. 3583–3593.
   PubMed Web of Science ®Google Scholar
• M.E. Cudkowicz, S. Titus, M. Kearney, H. Yu, A. Sherman, D. Schoenfeld, D. Hayden, A. Shui, B. Brooks, R. Conwit, D. Felsenstein, D.J. Greenblatt, M. Keroack, J.T. Kissel, R. Miller, J. Rosenfeld, J.D. Rothstein, E. Simpson, N. Tolkoff-Rubin, L. Zinman, and J.M. Shefner, Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: A multi-stage, randomised, double-blind, placebo-controlled trial, Lancet Neurol. 13 (2014), pp. 1083–1091.
   PubMed Web of Science ®Google Scholar
• M. Sisignano, M.J. Parnham, and G. Geisslinger, Drug repurposing for the development of novel analgesics, Trends Pharmacol. Sci. 37 (2016), pp. 172–183.
   PubMed Web of Science ®Google Scholar
• H. Fang, S.C. Harris, Z. Liu, G. Zhou, G. Zhang, J. Xu, L. Rosario, P.C. Howard, and W. Tong, FDA drug labeling: Rich resources to facilitate precision medicine, drug safety, and regulatory science, Drug Discov. Today 21 (2016), pp. 1566–1570.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration, FDA Online Label Repository, U.S. Food & Drug Administration, Silver Spring, MD, USA, 2017. Software available at https://labels.fda.gov/.
   Google Scholar
• National Center for Biotechnology Information, PubMed, National Center for Biotechnology Information, Bethesda, MD, USA, 2017; Software available at https://www.ncbi.nlm.nih.gov/pubmed.
   Google Scholar
• Canadian Institute of Health Research, DrugBank, Canadian Institute of Health Research, Ottawa, Canada, 2017. Software available at https://www.drugbank.ca/.
   Google Scholar
• Clarivate Analytics, Clarivate analytics integrity, Clarivate Analytics, Philadelphia, PA, USA, 2017. Software available at https://integrity.thomson-pharma.com/.
   Google Scholar
• A. Pettersson, E. Schwan, and B. Johansson, New alfentanil composition for the treatment of acute pain, Sweden, WO 2013/164620, 2013.
   Google Scholar
• MedicineNet, MedicineNet, MedicineNet, San Clemente, CA, USA, 2017. Software available at https://www.medicinenet.com/script/main/hp.asp.
   Google Scholar
• G. Addolorato, F. Caputo, E. Capristo, M. Domenicali, M. Bernardi, L. Janiri, R. Agabio, G. Colombo, G.L. Gessa, and G. Gasbarrini, Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study, Alcohol Alcohol. 37 (2002), pp. 504–508.
   PubMed Web of Science ®Google Scholar
• R.J. Gifford, Bethanidine sulfate—a new antihypertensive agent, JAMA 193 (1965), pp. 901–905.
   PubMed Web of Science ®Google Scholar
• M.B. Bacaner, M.F. Hoey, and M.G. Macres, Suppression of ventricular fibrillation and positive inotropic action of bethanidine sulfate, a chemical analog of bretylium tosylate that is well absorbed orally, Am. J. Cardiol. 49 (1982), pp. 45–55.
   PubMed Web of Science ®Google Scholar
• A. Romaniello, G. Viola, F. Salsano, and E. Rosato, In systemic sclerosis patients, Bosentan is safe and effective for digital ulcer prevention and it seems to attenuate the development of pulmonary arterial hypertension, Rheumatology 53 (2014), pp. 570–571.
   PubMed Web of Science ®Google Scholar
• A.F.G. Slater and A. Cerami, Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites, Nature 355 (1992), pp. 167–169.
   PubMed Web of Science ®Google Scholar
• L.-O. Roy, M.-B. Poirier, and D. Fortin, Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta, Invest. New Drugs 33 (2015), pp. 1020–1031.
   PubMed Web of Science ®Google Scholar
• W.-Y. Lee, W.-T. Lee, C.-H. Cheng, K.-C. Chen, C.-M. Chou, C.-H. Chung, M.S. Sun, H.W. Cheng, M.N. Ho, and C.W. Lin, Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1, Oncotarget 6 (2015), pp. 27580–27595.
   PubMed Web of Science ®Google Scholar
• S. Lee, D. Walker, and P. Zeitlin, Digitoxin treatment reduces nasal epithelial cytokines in cf subjects, FASEB J. 30 (2016), p. 1071.1.
   Google Scholar
• J.P. Vande Griend and S.L. Anderson, Histamine-1 receptor antagonism for treatment of insomnia, J. Am. Pharm. Assoc. 52 (2012), pp. e210–e219.
   Google Scholar
• L.R. Howard, ed., Gemcitabine: Pharmacology, clinical uses and potential side effects, 1st ed., Nova Science Pub Inc, Hauppauge, New York, 2014.
   Google Scholar
• B. Van Overmeire, I. Follens, S. Hartmann, W.L. Creten, and K.J. Van Acker, Treatment of patent ductus arteriosus with ibuprofen, Arch. Dis. Child. Fetal Neonatal Ed. 76 (1997), pp. F179–F184.
   PubMed Web of Science ®Google Scholar
• R.G. Bloch, A.S. Dooneief, A.S. Buchberg, and S. Spellman, The clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis, Ann. Intern. Med. 40 (1954), pp. 881–900.
   PubMed Web of Science ®Google Scholar
• R.A. Maxwell and S.B. Eckhardt, Drug discovery: A casebook and analysis, Clifton, NJ: Humana Press, 1990.
   Google Scholar
• G.S. Timmins and V. Deretic, Mechanisms of action of isoniazid, Mol. Microbiol. 62 (2006), pp. 1220–1227.
   PubMed Web of Science ®Google Scholar
• J. Kim, J.Y. Tang, R. Gong, J. Kim, J.J. Lee, K.V. Clemons, C.R. Chong, K.S. Chang, M. Fereshteh, D. Gardner, T. Reya, J.O. Liu, E.H. Epstein, D.A. Stevens, and P.A. Beachy, Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth, Cancer Cell 17 (2010), pp. 388–399.
   PubMed Web of Science ®Google Scholar
• J. Xu, Y. Dang, Y.R. Ren, and J.O. Liu, Cholesterol trafficking is required for mTOR activation in endothelial cells, Proc. Natl. Acad. Sci. U.S.A. 107 (2010), pp. 4764–4769.
   PubMed Web of Science ®Google Scholar
• J.W. Tilley and M.J. Kramer, Aminoadamantane derivatives, Prog. Med. Chem. 18 (1981), pp. 1–44.
   PubMedGoogle Scholar
• P.G. Rytik, V.F. Eremin, Z.B. Kvacheva, N.N. Poleschuk, S.A. Popov, H.C. Schroder, M. Bachmann, B.E. Weiler, and W.E. Müller, Susceptibility of primary human glial fibrillary acidic protein- positive brain cells to human immunodeficiency virus infection in vitro: Anti-HIV activity of memantine, AIDS Res. Hum. Retroviruses 7 (1991), pp. 89–95.
   PubMed Web of Science ®Google Scholar
• A. Uygun, A. Kadayifci, A.T. Isik, T. Ozgurtas, S. Deveci, A. Tuzun, Z. Yesilova, M. Gulsen, and K. Dagalp, Metformin in the treatment of patients with non-alcoholic steatohepatitis, Aliment. Pharmacol. Ther. 19 (2004), pp. 537–544.
   PubMed Web of Science ®Google Scholar
• M. Zakikhani, R. Dowling, I.G. Fantus, N. Sonenberg, and M. Pollak, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells, Cancer Res. 66 (2006), pp. 10269–10273.
   PubMed Web of Science ®Google Scholar
• J.L. Wright and J.L. Stanford, Metformin use and prostate cancer in Caucasian men: Results from a population-based case-control study, Cancer Causes Control 20 (2009), pp. 1617–1622.
   PubMed Web of Science ®Google Scholar
• T.P.C. Dorlo, M. Balasegaram, J.H. Beijnen, and P.J. de Vries, Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis, J. Antimicrob. Chemother. 67 (2012), pp. 2576–2597.
   PubMed Web of Science ®Google Scholar
• P.H. Gordon, D.H. Moore, D.F. Gelinas, C. Qualls, M.E. Meister, J. Werner, M. Mendoza, J. Mass, G. Kushner, and R.G. Miller, Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis, Neurology 62 (2004), pp. 1845–1847.
   PubMed Web of Science ®Google Scholar
• S. Zhu, I.G. Stavrovskaya, M. Drozda, B.Y.S. Kim, V. Ona, M. Li, S. Sarang, A.S. Liu, D.M. Hartley, D.C. Wu, S. Gullans, R.J. Ferrante, S. Przedborski, B.S. Kristal, and R.M. Friedlander, Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice, Nature 417 (2002), pp. 74–78.
   PubMed Web of Science ®Google Scholar
• R.M. Friedlander, M. Chen, V.O. Ona, M. Li, R.J. Ferrante, K.B. Fink, S. Zhu, J. Bian, L. Guo, L.A. Farrell, S.M. Hersch, W. Hobbs, J.P. Vonsattel, J.H. Cha, and R.M. Friedlander, Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease, Nat. Med. 6 (2000), pp. 797–801.
   PubMed Web of Science ®Google Scholar
• C. Herdeg, M. Oberhoff, D.I. Siegel-Axel, A. Baumbach, A. Blattner, A. Küttner, S. Schröder, and K.R. Karsch, Paclitaxel: A chemotherapeutic agent for prevention of restenosis? Experimental studies in vitro and in vivo, Z. Kardiol. 89 (2000), pp. 390–397.
   PubMedGoogle Scholar
• J.N. Poynter, S.B. Gruber, P.D.R. Higgins, R. Almog, J.D. Bonner, H.S. Rennert, M. Low, J.K. Greenson, and G. Rennert, Statins and the risk of colorectal cancer, N. Engl. J. Med. 352 (2005), pp. 2184–2192.
   PubMed Web of Science ®Google Scholar
• J.H. Kim and A.R. Scialli, Thalidomide: The tragedy of birth defects and the effective treatment of disease, Toxicol. Sci. 122 (2011), pp. 1–6.
   PubMed Web of Science ®Google Scholar
• D. Fourches, E. Muratov, and A. Tropsha, Trust, but verify II: A practical guide to chemogenomics data curation, J. Chem. Inf. Model. 56 (2016), pp. 1243–1252.
   PubMed Web of Science ®Google Scholar
• K. Mansouri, C.M. Grulke, A.M. Richard, R.S. Judson, and A.J. Williams, An automated curation procedure for addressing chemical errors and inconsistencies in publicdatasets used in QSAR modelling, SAR QSAR Environ. Res. 27 (2016), pp. 911–937.
   PubMed Web of Science ®Google Scholar
• H.A.M. Mucke, Drug repurposing patent applications April–June 2016, Assay Drug Dev. Technol. 14 (2016), pp. 573–576.
   Web of Science ®Google Scholar
• H.A.M. Mucke, Drug repurposing patent applications July–September 2016, Assay Drug Dev. Technol. 14 (2016), pp. 577–582.
   Web of Science ®Google Scholar
• H.A.M. Mucke, Drug repurposing patent applications October–December 2016, Assay Drug Dev. Technol. 15 (2017), pp. 120–126.
   Web of Science ®Google Scholar
• H.A.M. Mucke, Drug repurposing patent applications January–March 2017, Assay Drug Dev. Technol. 15 (2017), pp. 127–132.
   Web of Science ®Google Scholar
• Y.C. Martin, J.L. Kofron, and L.M. Traphagen, Do structurally similar molecules have similar biological activity?, J. Med. Chem. 45 (2002), pp. 4350–4358.
   PubMed Web of Science ®Google Scholar
• V. Poroikov, D. Akimov, E. Shabelnikova, and D. Filimonov, Top 200 medicines: Can new actions be discovered through computer-aided prediction?, SAR QSAR Environ. Res. 12 (2001), pp. 327–344.
   PubMed Web of Science ®Google Scholar
• M.J. Mancino, J. McGaugh, M.P. Chopra, J.B. Guise, C. Cargile, D.K. Williams, J. Thostenson, T.R. Kosten, N. Sanders, and A. Oliveto, Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms, J. Clin. Psychopharmacol. 34 (2014), pp. 234–239.
   PubMed Web of Science ®Google Scholar
• K. Takara, M. Matsubara, K. Yamamoto, T. Minegaki, S. Takegami, M. Takahashi, T. Yokoyama, and K. Okumura, Differential effects of calcium antagonists on ABCG2/BCRP-mediated drug resistance and transport in SN-38-resistant HeLa cells, Mol. Med. Rep. 5 (2012), pp. 603–609.
   PubMed Web of Science ®Google Scholar
• K.D. Rainsford, H. Omar, A. Ashraf, A.T. Hewson, R.A.D. Bunning, R. Rishiraj, P. Shepherd, and R.W. Seabrook, Recent pharmacodynamic and pharmacokinetic findings on oxaprozin, Inflammopharmacology 10 (2002), pp. 185–239.
   Google Scholar
• Q. Shi, J. Abusarah, G. Baroudi, J.C. Fernandes, H. Fahmi, and M. Benderdour, Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis, Arthritis Res. Ther. 14 (2012), p. R223.
   PubMed Web of Science ®Google Scholar
• S.A. Kryzhanovskii, R.M. Salimov, A.A. Lagunin, D.A. Filimonov, T.A. Gloriozova, and V.V. Poroikov, Nootropic action of some antihypertensive drugs: Computer predicting and experimental testing, Pharm. Chem. J. 45 (2012), pp. 605–611.
   Web of Science ®Google Scholar
• Y. Gao, R. O’Caoimh, L. Healy, D.M. Kerins, J. Eustace, G. Guyatt, D. Sammon, and D.W. Molloy, Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia, BMJ Open 3 (2013), pp. 1–8.
   Web of Science ®Google Scholar